Login / Signup

Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.

Yi-Han ChienGudrun WürthweinPablo ZubiaurBianca PosoccoMaría Angeles Pena PardoAlberto M BorobiaSara GagnoFrancisco Abad-SantosGeorg Hempel
Published in: Cancer chemotherapy and pharmacology (2022)
The two-compartment transit model adequately describes the absorption and distribution of imatinib in healthy volunteers. For patients, a lower clearance of imatinib compared to healthy volunteer was estimated by the model. The model can be applied for dose individualization based on trough concentrations assuming no significant differences in absorption between patients and healthy volunteers.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • chronic myeloid leukemia
  • patient reported